Literature DB >> 15155244

Anti-hepatitis B virus activity of ORI-9020, a novel phosphorothioate dinucleotide, in a transgenic mouse model.

Radhakrishnan P Iyer1, Arlene Roland, Yi Jin, Samir Mounir, Brent Korba, Justin G Julander, John D Morrey.   

Abstract

ORI-9020, a novel dinucleotide, evaluated in transgenic mice expressing hepatitis B virus (HBV), significantly reduced liver HBV DNA (P </= 0.001). Levels of HBeAg and HBsAg in serum and of HBcAg in liver were not affected by treatment. A minimal effective dosage was determined to be between 1.6 and 0.5 mg/kg of body weight/day, which was similar to that observed for adefovir dipivoxil.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15155244      PMCID： PMC415565          DOI： 10.1128/AAC.48.6.2318-2320.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  7 in total

1.  Utilization of transgenic mice replicating high levels of hepatitis B virus for antiviral evaluation of lamivudine.

Authors:  J D Morrey; K W Bailey; B E Korba; R W Sidwell
Journal:  Antiviral Res       Date:  1999-06       Impact factor: 5.970

2.  Interleukin-12 inhibits hepatitis B virus replication in transgenic mice.

Authors:  V J Cavanaugh; L G Guidotti; F V Chisari
Journal:  J Virol       Date:  1997-04       Impact factor: 5.103

Review 3.  Transgenic mice as a chemotherapeutic model for hepatitis B virus infection.

Authors:  J D Morrey; B E Korba; R W Sidwell
Journal:  Antivir Ther       Date:  1998

4.  Characterizing antiviral activity of adefovir dipivoxil in transgenic mice expressing hepatitis B virus.

Authors:  Justin G Julander; Robert W Sidwell; John D Morrey
Journal:  Antiviral Res       Date:  2002-07       Impact factor: 5.970

5.  Characterization of antiviral activity of entecavir in transgenic mice expressing hepatitis B virus.

Authors:  Justin G Julander; Richard J Colonno; Robert W Sidwell; John D Morrey
Journal:  Antiviral Res       Date:  2003-08       Impact factor: 5.970

6.  Phosphorothioate di- and trinucleotides as a novel class of anti-hepatitis B virus agents.

Authors:  Radhakrishnan P Iyer; Yi Jin; Arlene Roland; John D Morrey; Samir Mounir; Brent Korba
Journal:  Antimicrob Agents Chemother       Date:  2004-06       Impact factor: 5.191

7.  High-level hepatitis B virus replication in transgenic mice.

Authors:  L G Guidotti; B Matzke; H Schaller; F V Chisari
Journal:  J Virol       Date:  1995-10       Impact factor: 5.103
  7 in total
  13 in total

1.  Orally bioavailable anti-HBV dinucleotide acyloxyalkyl prodrugs.

Authors:  John E Coughlin; Seetharamaiyer Padmanabhan; Guangrong Zhang; Cassandra J Kirk; Chandrika P Govardhan; Brent E Korba; Kathleen O'Loughlin; Carol E Green; Jon Mirsalis; John D Morrey; Radhakrishnan P Iyer
Journal:  Bioorg Med Chem Lett       Date:  2010-01-11       Impact factor: 2.823

2.  RAPID FUNCTIONALIZATION AND LOADING OF SOLID SUPPORTS.

Authors:  Radhakrishnan P Iyer; John E Coughlin; Seetharamaiyer Padmanabhan
Journal:  Org Prep Proced Int       Date:  2005-06       Impact factor: 1.628

3.  Breaking B and T cell tolerance using cationic lipid--DNA complexes (CLDC) as a vaccine adjuvant with hepatitis B virus (HBV) surface antigen in transgenic mice expressing HBV.

Authors:  John D Morrey; Neil E Motter; Stella Chang; Jeffery Fairman
Journal:  Antiviral Res       Date:  2011-04-23       Impact factor: 5.970

4.  Metabolism, pharmacokinetics, tissue distribution, and stability studies of the prodrug analog of an anti-hepatitis B virus dinucleoside phosphorothioate.

Authors:  John E Coughlin; Rajendra K Pandey; Seetharamaiyer Padmanabhan; Kathleen G O'Loughlin; Judith Marquis; Carol E Green; Jon C Mirsalis; Radhakrishnan P Iyer
Journal:  Drug Metab Dispos       Date:  2012-02-10       Impact factor: 3.922

5.  Efficacy of cationic lipid-DNA complexes (CLDC) on hepatitis B virus in transgenic mice.

Authors:  John D Morrey; Neil E Motter; Brandon Taro; Marla Lay; Jeffery Fairman
Journal:  Antiviral Res       Date:  2008-02-25       Impact factor: 5.970

6.  Alkoxyalkyl esters of 9-(s)-(3-hydroxy-2-phosphonomethoxypropyl) adenine are potent and selective inhibitors of hepatitis B virus (HBV) replication in vitro and in HBV transgenic mice in vivo.

Authors:  John D Morrey; Brent E Korba; James R Beadle; David L Wyles; Karl Y Hostetler
Journal:  Antimicrob Agents Chemother       Date:  2009-04-27       Impact factor: 5.191

7.  Evaluation of single and combination therapies with tenofovir disoproxil fumarate and emtricitabine in vitro and in a robust mouse model supporting high levels of hepatitis B virus replication.

Authors:  Raymond F Schinazi; Leda Bassit; Marcia M Clayton; Bill Sun; James J Kohler; Aleksandr Obikhod; Alla Arzumanyan; Mark A Feitelson
Journal:  Antimicrob Agents Chemother       Date:  2012-09-17       Impact factor: 5.191

8.  Anti-hepatitis B virus effect and possible mechanism of action of 3,4-o-dicaffeoylquinic Acid in vitro and in vivo.

Authors:  Yi-Hang Wu; Bing-Jie Hao; Hong-Cui Cao; Wei Xu; Yong-Jun Li; Lan-Juan Li
Journal:  Evid Based Complement Alternat Med       Date:  2012-06-03       Impact factor: 2.629

9.  Antiviral Efficacy and Host Innate Immunity Associated with SB 9200 Treatment in the Woodchuck Model of Chronic Hepatitis B.

Authors:  Kyle E Korolowicz; Radhakrishnan P Iyer; Stefanie Czerwinski; Manasa Suresh; Junming Yang; Seetharamaiyer Padmanabhan; Anjaneyulu Sheri; Rajendra K Pandey; Jeffrey Skell; Judith K Marquis; Bhaskar V Kallakury; Robin D Tucker; Stephan Menne
Journal:  PLoS One       Date:  2016-08-23       Impact factor: 3.240

10.  Antiviral Efficacy and Host Immune Response Induction during Sequential Treatment with SB 9200 Followed by Entecavir in Woodchucks.

Authors:  Manasa Suresh; Kyle E Korolowicz; Maria Balarezo; Radhakrishnan P Iyer; Seetharamaiyer Padmanabhan; Dillon Cleary; Rayomand Gimi; Anjaneyulu Sheri; Changsuek Yon; Bhaskar V Kallakury; Robin D Tucker; Nezam Afdhal; Stephan Menne
Journal:  PLoS One       Date:  2017-01-05       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.